4.28

4.04% -0.18

Onkure Therapeutics Inc (OKUR)

Overview News Price History Discussions Forecast

Onkure Therapeutics Inc stock is traded at $4.28, with a volume of 193.80K. It is down -4.04% in the last 24 hours and up +2.15% over the past month. OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.

Previous Close:

$4.46

Open:

$4.45

24h Volume:

193.80K

Relative Volume:

0.65

Market Cap:

$172.89M

Revenue:

Net Income/Loss:

$-58.75M

P/E Ratio:

-0.9891

EPS:

-4.327

Net Cash Flow:

$-50.79M

1W Performance:

-6.55%

1M Performance:

+2.15%

6M Performance:

+36.31%

1Y Performance:

+67.84%

1-Day Range:

$4.17

$4.45

1-Week Range:

$4.155

$4.76

52-Week Range:

$1.91

$5.38

Onkure Therapeutics Inc Stock (OKUR) Company Profile

Name

Onkure Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(720) 307-2892

Address

6707 WINCHESTER CIRCLE, SUITE 400, BOULDER

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

OKUR's Discussions on Twitter

Compare OKUR vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OKUR Onkure Therapeutics Inc	4.28	172.89M	0	-58.75M	-50.79M	-4.327
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-30-25	Initiated	Evercore ISI	Outperform
Dec-05-24	Initiated	Leerink Partners	Outperform
Oct-10-24	Initiated	Oppenheimer	Outperform
Dec-15-23	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-15-23	Downgrade	Jefferies	Buy → Hold
Dec-15-23	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-14-23	Downgrade	BofA Securities	Buy → Underperform
Dec-14-23	Downgrade	Ladenburg Thalmann	Buy → Neutral
Dec-14-23	Downgrade	Piper Sandler	Overweight → Neutral
Dec-14-23	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-14-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-15-23	Initiated	William Blair	Outperform
Aug-28-23	Initiated	H.C. Wainwright	Buy
Jul-03-23	Initiated	BofA Securities	Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy
Jan-27-22	Initiated	Robert W. Baird	Outperform
Dec-21-21	Initiated	H.C. Wainwright	Buy
Nov-22-21	Initiated	Ladenburg Thalmann	Buy
May-04-21	Initiated	Jefferies	Buy
May-04-21	Initiated	Piper Sandler	Overweight
May-04-21	Initiated	SVB Leerink	Outperform

View All

Onkure Therapeutics Inc Stock (OKUR) Latest News

Jul 08, 2026

ETFs Investing in OnKure Therapeutics, Inc. Class A Stocks - TradingView

Jul 08, 2026

Jul 06, 2026

Enterprise value to EBITDA forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView

Jul 06, 2026

Jul 02, 2026

OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026 - The Manila Times

Jul 02, 2026

OnKure lines up July 15 virtual event on cancer-drug design - Stock Titan

Jul 02, 2026

Jun 29, 2026

OnKure Therapeutics, Inc.(NasdaqGM: OKUR) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

OnKure Therapeutics, Inc.(NasdaqGM:OKUR) added to Russell Small Cap Completeness Index - marketscreener.com

Jun 28, 2026

OnKure Therapeutics, Inc.(NasdaqGM:OKUR) added to Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 26, 2026

OnKure Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:OKUR) - TradingView

Jun 26, 2026

Jun 25, 2026

OKUR Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and CalciMedica (CALC) - The Globe and Mail

Jun 25, 2026

Jun 24, 2026

OnKure Therapeutics president and CEO sells $378 in stock By Investing.com - Investing.com Nigeria

Jun 24, 2026

OnKure Therapeutics president and CEO sells $378 in stock - Investing.com

Jun 24, 2026

OnKure Therapeutics CFO Jason Leverone sells $1,332 in stock - Investing.com

Jun 24, 2026

Form 4 Onkure Therapeutics Inc For: 24 June By Investing.com - Investing.com Nigeria

Jun 24, 2026

OnKure Therapeutics CFO Jason Leverone sells $1,332 in stock By Investing.com - Investing.com Nigeria

Jun 24, 2026

[Form 4] OnKure Therapeutics, Inc. Insider Trading Activity - Stock Titan

Jun 24, 2026

OnKure Therapeutics (OKUR) CFO auto-sells shares to cover RSU tax withholding - Stock Titan

Jun 24, 2026

Jun 22, 2026